Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunotherapy network.

Détails

ID Serval
serval:BIB_954B2D965E56
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunotherapy network.
Périodique
Journal of Nuclear Medicine
Auteur(s)
Hohloch K., Delaloye A.B., Windemuth-Kieselbach C., Gómez-Codina J., Linkesch W., Jurczak W., Cacchione R., Suh C., Zinzani P.L., Trümper L.
ISSN
1535-5667 (Electronic)
ISSN-L
0161-5505
Statut éditorial
Publié
Date de publication
2011
Volume
52
Numéro
9
Pages
1354-1360
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside randomized clinical studies. The RIT-N collects unbiased data on treatment indications, disease stages, patients' conditions, lymphoma subtypes, and hematologic side effects of radioimmunotherapy treatment. Methods: RIT-N is located at the University of Gottingen, Germany, and collected data from 14 countries. Data were entered by investigators into a Web-based central database managed by an independent clinical research organization. Results: Patients (1,075) were enrolled from December 2006 until November 2009, and 467 patients with an observation time of at least 12 mo were included in the following analysis. Diagnoses were as follows: 58% follicular lymphoma and 42% other B-cell lymphomas. The mean overall survival was 28 mo for follicular lymphoma and 26 mo for other lymphoma subtypes. Hematotoxicity was mild for hemoglobin (World Health Organization grade II), with a median nadir of 10 g/dL, but severe (World Health Organization grade III) for platelets and leukocytes, with a median nadir of 7,000/mu L and 2.2/mu L, respectively. Conclusion: Clinical usage of radioimmunotherapy differs from the labeled indications and can be assessed by this registry, enabling analyses of outcome and toxicity data beyond clinical trials. This analysis proves that radioimmunotherapy in follicular lymphoma and other lymphoma subtypes is a safe and efficient treatment option.
Pubmed
Web of science
Création de la notice
23/09/2011 13:42
Dernière modification de la notice
03/03/2018 19:39
Données d'usage